Nuwellis Reports 14.1% Revenue Growth in Q2 2026, Net Loss Decreases

Nuwellis, Inc. reported its financial results for the second quarter of 2026, revealing a net sales increase of 14.1% to $1.97 million compared to $1.73 million in the same period last year. For the first half of 2026, the company achieved net sales of $4.37 million, a 20.5% increase from $3.63 million in the first half of 2025. The growth in revenue was primarily driven by a significant 209% increase in console sales and a 9% rise in circuit sales, reflecting a higher number of patients treated with the Aquadex therapy.

Despite the revenue growth, Nuwellis reported a net loss of $4.83 million for the second quarter, a decrease from a loss of $12.55 million in the prior year. The loss for the first half of 2026 was $9.37 million, down from $15.57 million in the same period of 2025. The company attributed the improved financial performance to a reduction in the cost of goods sold, which fell by 38.6% in the second quarter, largely due to a shift to contract manufacturing. However, operating expenses increased, with selling, general, and administrative expenses rising by 16.8% and research and development expenses increasing by 39.6%.

In terms of strategic developments, Nuwellis completed the acquisition of Rendiatech Ltd. on March 17, 2026, which was accounted for as an asset acquisition. This acquisition is expected to enhance the company's product offerings and market position. Additionally, the company executed a public offering on June 8, 2026, raising approximately $6 million in gross proceeds, which will support its operational and growth initiatives. The company also underwent a one-for-thirty-five reverse stock split effective June 25, 2026, aimed at improving its stock price and compliance with Nasdaq listing requirements.

Operationally, Nuwellis reported a significant increase in its customer base, with a notable rise in the number of patients treated using the Aquadex therapy. The company has streamlined its operations to focus on the U.S. market, where it has seen the strongest growth and clinical demand. As of June 30, 2026, Nuwellis had cash and cash equivalents of $4.0 million, a substantial increase from $1.2 million at the end of 2025, reflecting successful financing activities.

Looking ahead, Nuwellis anticipates continued growth in sales and product adoption, although it expects to incur losses in the near term. The company plans to seek additional financing to support its operations and growth initiatives, particularly in integrating the Rendiatech technology. While management is optimistic about its ability to fund operations and execute its strategic plan, it acknowledges the uncertainty surrounding future capital availability and the potential for ongoing operating losses.